These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35324534)

  • 21. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.
    Chen L; Ye HL; Zhang G; Yao WM; Chen XZ; Zhang FC; Liang G
    PLoS One; 2014; 9(1):e85771. PubMed ID: 24465696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triptolide Inhibits Invasion and Tumorigenesis of Hepatocellular Carcinoma MHCC-97H Cells Through NF-κB Signaling.
    Wang H; Ma D; Wang C; Zhao S; Liu C
    Med Sci Monit; 2016 May; 22():1827-36. PubMed ID: 27239780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
    Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
    Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma.
    Ma Z; Guo D; Wang Q; Liu P; Xiao Y; Wu P; Wang Y; Chen B; Liu Z; Liu Q
    Theranostics; 2019; 9(10):2967-2983. PubMed ID: 31244936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aidi injection enhances the anti-tumor impact of doxorubicin in H22 tumor-containing mice.
    Lu Y; Zhang S; Zhu X; Wang K; He Y; Liu C; Sun J; Pan J; Zheng L; Liu W; Li Y; Huang Y; Liu T
    J Ethnopharmacol; 2023 Mar; 303():115968. PubMed ID: 36473617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aptamer-mediated doxorubicin delivery reduces HCC burden in 3D organoids model.
    Zhou K; Huo X; Nguyen R; Bae SDW; Han S; Zhang Z; Duan W; Yuen L; Lam V; George J; Qiao L
    J Control Release; 2022 Jan; 341():341-350. PubMed ID: 34848243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hsa_circ_0000098 is a novel therapeutic target that promotes hepatocellular carcinoma development and resistance to doxorubicin.
    Li Y; Wu A; Chen L; Cai A; Hu Y; Zhou Z; Qi Q; Wu Y; Xia D; Dong P; Ju S; Wang F
    J Exp Clin Cancer Res; 2022 Sep; 41(1):267. PubMed ID: 36071480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
    Long L; Xiang H; Liu J; Zhang Z; Sun L
    Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis.
    Cao Y; Zhang F; Wang H; Bi C; Cui J; Liu F; Pan H
    Mol Cell Biochem; 2021 Jan; 476(1):279-292. PubMed ID: 32965597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
    You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
    Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.
    Zhang Y; Wu W; Sun Q; Ye L; Zhou D; Wang W
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.
    Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
    Oncotarget; 2014 May; 5(9):2853-63. PubMed ID: 24797310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ellagic acid synergistically potentiates inhibitory activities of chemotherapeutic agents to human hepatocellular carcinoma.
    Zhong C; Qiu S; Li J; Shen J; Zu Y; Shi J; Sui G
    Phytomedicine; 2019 Jun; 59():152921. PubMed ID: 31055231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through Its interactions with PCNA and USP1.
    Lee KY; Yang K; Cohn MA; Sikdar N; D'Andrea AD; Myung K
    J Biol Chem; 2010 Apr; 285(14):10362-9. PubMed ID: 20147293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
    Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation.
    Chen G; Wang Y; Zhao X; Xie XZ; Zhao JG; Deng T; Chen ZY; Chen HB; Tong YF; Yang Z; Ding XW; Guo PY; Yu HT; Wu LJ; Zhang SN; Zhu QD; Li JJ; Shan YF; Yu FX; Yu ZP; Xia JL
    J Exp Clin Cancer Res; 2021 Jun; 40(1):218. PubMed ID: 34193219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
    Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
    Tumour Biol; 2020 Apr; 42(4):1010428320914475. PubMed ID: 32252611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.